GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Price-to-Owner-Earnings

H. Lundbeck AS (FRA:LDBB) Price-to-Owner-Earnings : 22.79 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Price-to-Owner-Earnings?

As of today (2024-06-05), H. Lundbeck AS's share price is €4.33. H. Lundbeck AS's Owner Earnings per Share (TTM) ended in Mar. 2024 was €0.19. It's Price-to-Owner-Earnings for today is 22.79.


The historical rank and industry rank for H. Lundbeck AS's Price-to-Owner-Earnings or its related term are showing as below:

FRA:LDBB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.06   Med: 35.32   Max: 128.23
Current: 22.98

During the past 13 years, the highest Price-to-Owner-Earnings of H. Lundbeck AS was 128.23. The lowest was 19.06. And the median was 35.32.


FRA:LDBB's Price-to-Owner-Earnings is ranked better than
54.74% of 422 companies
in the Drug Manufacturers industry
Industry Median: 26.12 vs FRA:LDBB: 22.98

As of today (2024-06-05), H. Lundbeck AS's share price is €4.33. H. Lundbeck AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.33. Therefore, H. Lundbeck AS's PE Ratio for today is 13.28.

As of today (2024-06-05), H. Lundbeck AS's share price is €4.33. H. Lundbeck AS's EPS without NRI for the trailing twelve months (TTM) ended in was €0.33. Therefore, H. Lundbeck AS's PE Ratio without NRI for today is 13.28.

During the past 13 years, H. Lundbeck AS's highest PE Ratio without NRI was 22.17. The lowest was 11.21. And the median was 12.76.


H. Lundbeck AS Price-to-Owner-Earnings Historical Data

The historical data trend for H. Lundbeck AS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Price-to-Owner-Earnings Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 24.49 31.97

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.92 36.76 34.22 31.97 19.99

Competitive Comparison of H. Lundbeck AS's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Price-to-Owner-Earnings falls into.



H. Lundbeck AS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

H. Lundbeck AS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.33/0.19
=22.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


H. Lundbeck AS  (FRA:LDBB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


H. Lundbeck AS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (FRA:LDBB) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (FRA:LDBB) Headlines

No Headlines